In addition, concurrent ANGPTL4 and NOX4 expression was significantly present in patients with late-stage CRC, which suggests that a treatment that combines targeting of ANGPTL4 and the use of antioxidants could be considered for recurrent and metastatic CRC. This evidence concerns the gene ANGPTL4 and colorectal carcinoma.